Mattia D'Agostino1, Mario Boccadoro1, Eric L Smith2. 1. Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy. 2. Myeloma Service, Cellular Therapeutics Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. smithe3@mskcc.org.
Abstract
PURPOSE OF REVIEW: The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients' survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies. RECENT FINDINGS: Clinical trials exploring these immunotherapies to treat myeloma are now well underway and show promising results. In relapsed myeloma, monoclonal antibodies directed against plasma cell antigens and immune checkpoints have already shown substantial efficacy. In parallel, trials of adoptive cellular therapy have exciting promise in myeloma, having induced dramatic responses in a handful of early study participants. Taken together, immunotherapeutic approaches hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.
PURPOSE OF REVIEW: The treatment landscape of multiple myeloma is rapidly changing; however, despite improvement in patients' survival, it still remains a largely incurable disease. One hallmark of myeloma is substantial immune dysfunction leading to an increased infection rate and the inability of immune surveillance to detect neoplastic cells. Here, we critically analyze clinical approaches to harness the immune system to overcome this defect with a focus on antibody based and adoptive cellular therapies. RECENT FINDINGS: Clinical trials exploring these immunotherapies to treat myeloma are now well underway and show promising results. In relapsed myeloma, monoclonal antibodies directed against plasma cell antigens and immune checkpoints have already shown substantial efficacy. In parallel, trials of adoptive cellular therapy have exciting promise in myeloma, having induced dramatic responses in a handful of early study participants. Taken together, immunotherapeutic approaches hold enormous potential in the field of multiple myeloma and in the near future can be combined with or even replace the current standard of care.
Entities:
Keywords:
BCMA; CAR T cell; CD38; Cellular therapy; Checkpoint blockade; PD-1
Authors: Niels W C J van de Donk; Philippe Moreau; Torben Plesner; Antonio Palumbo; Francesca Gay; Jacob P Laubach; Fabio Malavasi; Hervé Avet-Loiseau; Maria-Victoria Mateos; Pieter Sonneveld; Henk M Lokhorst; Paul G Richardson Journal: Blood Date: 2015-12-02 Impact factor: 22.113
Authors: Kimberly A Noonan; Carol A Huff; Janice Davis; M Victor Lemas; Susan Fiorino; Jeffrey Bitzan; Anna Ferguson; Amy Emerling; Leo Luznik; William Matsui; Jonathan Powell; Ephraim Fuchs; Gary L Rosner; Caroline Epstein; Lakshmi Rudraraju; Richard F Ambinder; Richard J Jones; Drew Pardoll; Ivan Borrello Journal: Sci Transl Med Date: 2015-05-20 Impact factor: 17.956
Authors: Andrzej Jakubowiak; Massimo Offidani; Brigitte Pégourie; Javier De La Rubia; Laurent Garderet; Kamel Laribi; Alberto Bosi; Roberto Marasca; Jacob Laubach; Ann Mohrbacher; Angelo Michele Carella; Anil K Singhal; L Claire Tsao; Mark Lynch; Eric Bleickardt; Ying-Ming Jou; Michael Robbins; Antonio Palumbo Journal: Blood Date: 2016-04-18 Impact factor: 22.113
Authors: Cameron J Turtle; Laïla-Aïcha Hanafi; Carolina Berger; Theodore A Gooley; Sindhu Cherian; Michael Hudecek; Daniel Sommermeyer; Katherine Melville; Barbara Pender; Tanya M Budiarto; Emily Robinson; Natalia N Steevens; Colette Chaney; Lorinda Soma; Xueyan Chen; Cecilia Yeung; Brent Wood; Daniel Li; Jianhong Cao; Shelly Heimfeld; Michael C Jensen; Stanley R Riddell; David G Maloney Journal: J Clin Invest Date: 2016-04-25 Impact factor: 14.808
Authors: Meletios A Dimopoulos; Albert Oriol; Hareth Nahi; Jesus San-Miguel; Nizar J Bahlis; Saad Z Usmani; Neil Rabin; Robert Z Orlowski; Mieczyslaw Komarnicki; Kenshi Suzuki; Torben Plesner; Sung-Soo Yoon; Dina Ben Yehuda; Paul G Richardson; Hartmut Goldschmidt; Donna Reece; Steen Lisby; Nushmia Z Khokhar; Lisa O'Rourke; Christopher Chiu; Xiang Qin; Mary Guckert; Tahamtan Ahmadi; Philippe Moreau Journal: N Engl J Med Date: 2016-10-06 Impact factor: 91.245
Authors: H J Pegram; T J Purdon; D G van Leeuwen; K J Curran; S A Giralt; J N Barker; R J Brentjens Journal: Leukemia Date: 2014-07-09 Impact factor: 11.528
Authors: Camille Guillerey; Kyohei Nakamura; Andrea C Pichler; Deborah Barkauskas; Sophie Krumeich; Kimberley Stannard; Kim Miles; Heidi Harjunpää; Yuan Yu; Mika Casey; Alina I Doban; Mircea Lazar; Gunter Hartel; David Smith; Slavica Vuckovic; Michele Wl Teng; P Leif Bergsagel; Marta Chesi; Geoffrey R Hill; Ludovic Martinet; Mark J Smyth Journal: JCI Insight Date: 2019-06-13